Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin for CDI Prevention
NCT04241744Phase 4Withdrawn
- Sponsor
- Creighton University
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by Creighton University. Planned start Oct 2019; status: withdrawn.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04241744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241744.